Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 3Warts 2Keratosis, Actinic 2Hyperthermia 2Hematologic Neoplasms 2Hemangioma 2Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pelvic Neoplasms 1Pain 1Obesity 1Nonmelanoma Skin Cancers 1Mucositis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Melanoma 1Kidney Neoplasms 1Invasive Fungal Infections 1Insulinoma 1Infertility, Female 1Infertility 1Inappropriate Prescribing 1Hyperinsulinism 1Hemorrhage 1Head and Neck Carcinoma 1

Interventions

fluorodopa F 18 3pasireotide 1dapagliflozin 1amino-acid, glucose, and electrolyte solution 1Surveys and Questionnaires 1Sugars 1Solutions 1Saline Solution 1Pioglitazone 1Metformin 1Insulin 1Injections 1Diazoxide 1Amino Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hyperinsulinism × Solutions × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡